A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Dulaglutide (Primary) ; Insulin glargine; Insulin lispro
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AWARD-7
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 15 Feb 2017 Status changed from active, no longer recruiting to completed.
- 25 Feb 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016, according to ClinicalTrials.gov record.